Chelsea E Jones

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Ryan K. Shields, Erin K McCreary, Rachel V Marini et al. · Clinical Infectious Diseases · 2019 · 98 citations · Full text

Medical Microbiology, Antimicrobial Susceptibility, Health Sciences +14

Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>

William R. Wilson, Ellen G Kline, Chelsea E Jones et al. · Antimicrobial Agents and Chemotherapy · 2019 · 81 citations · Full text

<i>In Vitro</i> Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

Abigail M Rubio, Ellen G Kline, Chelsea E Jones et al. · Antimicrobial Agents and Chemotherapy · 2021 · 60 citations · Full text

Impact of<i>ompk36</i>genotype and KPC subtype on the<i>in vitro</i>activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing<i>K. pneumoniae</i>clinical isolates

Tara M Rogers, Ellen G Kline, M. Patrick Griffith et al. · JAC-Antimicrobial Resistance · 2023 · 13 citations · Full text

Differential <i>in vitro</i> susceptibility to ampicillin/ceftriaxone combination therapy among <i>Enterococcus faecalis</i> infective endocarditis clinical isolates

Kevin J. Westbrook, Gayatri Shankar Chilambi, Madison E. Stellfox et al. · Journal of Antimicrobial Chemotherapy · 2024 · 12 citations · Full text